
News • Medication quality
No clear evidence that most new cancer drugs extend or improve life
The majority of cancer drugs approved in Europe between 2009 and 2013 entered the market without clear evidence that they improved survival or quality of life for patients, finds a study published by The BMJ. Even where drugs did show survival gains over existing treatments, these were often marginal, the results show. Many of the drugs were approved on the basis of indirect (‘surrogate’)…
























